Fam-trastuzumab deruxtecan (T-DXd) is FDA approved for metastatic HER2-positive (HER2+) and HER2-low breast cancer (BC). Peripheral neuropathy is a side effect of T-DXd, with an incidence of 13%. Here we discuss two BC patients (pts) who presented with paresthesias of the trunk ...
According to these two investigations, FAM83A is an essential signal transduction component of HER2+ BCs and may serve as a novel therapeutic target for both trastuzumab-sensitive and trastuzumab-resistant malignancies. Several subsequent studies have shown a correlation between FAM83A and EGFR [22]...